Commenced in January 2007
Frequency: Monthly
Edition: International
Paper Count: 30123
Radiochemical Purity of 68Ga-BCA-Peptides: Separation of All 68Ga Species with a Single iTLC Strip

Authors: Anton A. Larenkov, Alesya Ya Maruk

Abstract:

In the present study, highly effective iTLC single strip method for the determination of radiochemical purity (RCP) of 68Ga-BCA-peptides was developed (with no double-developing, changing of eluents or other additional manipulation). In this method iTLC-SG strips and commonly used eluent TFAaq. (3-5 % (v/v)) are used. The method allows determining each of the key radiochemical forms of 68Ga (colloidal, bound, ionic) separately with the peaks separation being no less than 4 σ. Rf = 0.0-0.1 for 68Ga-colloid; Rf = 0.5-0.6 for 68Ga-BCA-peptides; Rf = 0.9-1.0 for ionic 68Ga. The method is simple and fast: For developing length of 75 mm only 4-6 min is required (versus 18-20 min for pharmacopoeial method). The method has been tested on various compounds (including 68Ga-DOTA-TOC, 68Ga-DOTA-TATE, 68Ga-NODAGA-RGD2 etc.). The cross-validation work for every specific form of 68Ga showed good correlation between method developed and control (pharmacopoeial) methods. The method can become convenient and much more informative replacement for pharmacopoeial methods, including HPLC.

Keywords: DOTA-TATE, 68Ga, quality control, radiochemical purity, radiopharmaceuticals, iTLC.

Digital Object Identifier (DOI): doi.org/10.5281/zenodo.1126784

Procedia APA BibTeX Chicago EndNote Harvard JSON MLA RIS XML ISO 690 PDF Downloads 1260

References:


[1] European Directorate for the Quality of Medicines & Healthcare (EDQM). Gallium (68Ga) edotreotide injection. European Pharmacopoeia 8.0. 01/2013:2482:4847–48.
[2] Eidherr, H., Girschele, F., Mitterhauser, M. and Wadsak, W. Synthesis of (68Ga)Gallium Dota-(Tyr3)-Octreotide Acetate ((68Ga)-Dotatoc) (2012) p.321-332, in Radiochemical Syntheses: Radiopharmaceuticals for Positron Emission Tomography, Volume 1 (eds. P. J. H. Scott and B. G. Hockley), John Wiley & Sons, Inc., Hoboken, NJ, USA. doi:10.1002/9781118140345.ch32.
[3] Mukherjee A., Pandey U., Chakravarty R., Sarma H.D., Dash A. Single vial kit formulation for preparation of PET radiopharmaceutical: 68Ga-DOTA-TOC. J Radioanal Nucl Chem (2014) 302:1253–1258, doi:10.1007/s10967-014-3643-7.
[4] Blom E., Koziorowski J. 68Ga-Autoclabeling of DOTA-TATE and DOTA-NOC. Appl Radiat Isot (2012) 70:980-983, doi:10.1016/j.apradiso.2012.03.032.
[5] Ali M., Hsieh W. and Tsopelas C. An improved assay for 68Ga-hydroxide in 68Ga-DOTATATE formulations intended for neuroendocrine tumour imaging. J Label Compd Radiopharm (2015) 58:383–389, doi:10.1002/jlcr.3318.
[6] Aslani A, Snowdon GM, Bailey DL, Schembri GP, Bailey EA, Roach PJ. Gallium‐68 DOTATATE Production with Automated PET Radiopharmaceutical Synthesis System: A Three Year Experience. Asia Oceania J Nucl Med Biol (2014) 2(2):75‐86.
[7] Larenkov A. A., Bruskin A. B. and Kodina G. E. Preparation of High-Purity 68Ga Solutions by Ion Exchange in Mixed Acetone–Hydrochloric Acid Medium. Radiochemistry (2014) 56:57–65, doi:10.1134/S1066362214010123.
[8] Larenkov A. A., Bruskin A. B. and Kodina G. E. Preparation of highly purified 68Ga solutions via ion exchange in hydrochloric acid–ethanol mixtures. J Radioanal Nucl Chem (2015) 305:147-160, doi:10.1007/s10967-015-4089-2.
[9] Schultz M., Mueller D., Baum R., Watkins G., Breeman W. A new automated NaCl based robust method for routine production of gallium-68 labeled peptides. Appl Radiat Isot (2013) 76:46-54, doi:10.1016/j.apradiso.2012.08.011.
[10] Ocak M., Antretter M., Knopp R., Kunkel F., Petrik M., Bergisadi N., Decristoforo C. Full automation of 68Ga labelling of DOTA-peptides including cation exchange prepurification. Appl Radiat Isot (2010) 68:297–302, doi:10.1016/j.apradiso.2009.10.006.
[11] Baur B., Solbach C., Andreolli E., Winter G., Machulla H.-J., Reske S.N. Synthesis, Radiolabelling and In Vitro Characterization of the Gallium-68-, Yttrium-90- and Lutetium-177-Labelled PSMA Ligand, CHX-A''-DTPA-DUPA-Pep. Pharmaceuticals (2014) 7:517-529, doi:10.3390/ph7050517.
[12] Sharma V., Prior J.L., Belinsky M.G., Kruh G.D. and Piwnica-Worms D. Characterization of a 67Ga/68Ga Radiopharmaceutical for SPECT and PET of MDR1 P-Glycoprotein Transport Activity In Vivo: Validation in Multidrug-Resistant Tumors and at the Blood–Brain Barrier. J Nucl Med (2005) 46:354 –364.
[13] Vis R., Lavalaye J., van de Garde E.M.W. GMP-compliant 68Ga radiolabelling in a conventional small-scale radiopharmacy: a feasible approach for routine clinical use. EJNMMI Research (2015) 5:27, doi:10.1186/s13550-015-0105-3.
[14] Aghanejad A., Jalilian A.R., Maus S., Yousefnia H., Geramifar P., Beiki D. Optimized production and quality control of 68Ga-DOTATATE. Iran J Nucl Med (2016) 24:29-36.
[15] Banerjee S.R., Chen Z., Pullambhatla M., Lisok A., Chen J., Mease R.C. and Pomper M.G. Preclinical Comparative Study of 68Ga-Labeled DOTA, NOTA, and HBED-CC Chelated Radiotracers for Targeting PSMA. Bioconjugate Chemistry (2016) 27(6):1447-1455, doi:10.1021/acs.bioconjchem.5b00679.
[16] Eder M., Neels O., Müller M., Bauder-Wüst U., Remde Y., Schäfer M., Hennrich U., Eisenhut M., Afshar-Oromieh A., Haberkorn U., Kopka K. Novel Preclinical and Radiopharmaceutical Aspects of (68Ga)Ga-PSMA-HBED-CC: A New PET Tracer for Imaging of Prostate Cancer. Pharmaceuticals (2014) 7:779-796, doi:10.3390/ph7070779.
[17] Zoghi M., Jalilian A.R., Niazi A., Johari-Daha F., Alirezapour B., Ramezanpour S. Development of a 68Ga-peptide tracer for PET GnRH1-imaging. Ann Nucl Med (2016) 30(6):400-8, doi:10.1007/s12149-016-1074-y.
[18] European Directorate for the Quality of Medicines & Healthcare (EDQM). Radiopharmaceutical preparations. European Pharmacopoeia 8.0. 01/2014:0125:759-63.